Chemomab Therapeutics Ltd. (CMMB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CMMB
- Company Chemomab Therapeutics Ltd.
- Price $2
- Changes Percentage -2.91
- Change -0.06
- Day Low $1.94
- Day High $2.05
- Year High $6.1
- Year Low $1.35
- Market Cap $12,187,130
- Price Avg 50 EMA (D) $1.69
- Price Avg 200 EMA (D) $3.08
- Exchange NASDAQ
- Volume 109,376
- Average Volume 90,127
- Open $2.04
- Previous Close $2.06
- EPS -1.44
- PE -1.37
- Earnings Announcement 2026-03-11 12:00:00
- Shares Outstanding $6,155,116
Company brief: CHEMOMAB THERAPEUTICS LTD. (CMMB )
- Healthcare
- Biotechnology
- Dr. Adi Mor George Ph.D.
- https://www.chemomab.com
- IL
- N/A
- 02-12-2019
- US16385C1045
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.